spn ppt

64
Solitary Pulmonary Nodule

Upload: abinash66

Post on 21-Jan-2017

391 views

Category:

Education


0 download

TRANSCRIPT

Page 1: Spn ppt

Solitary Pulmonary Nodule

Page 2: Spn ppt

Definition of SPN

• SPN: Solitary, circumscribed, pulmonary opacity with no associated pulmonary, pleural, or mediastinal abnormality, measuring less than 3 cm in diameter

• About 40% malignant• Lung mass: greater than 3 cm

– Vast majority are malignant

Page 3: Spn ppt

Differential Diagnosis of SPN

• Neoplasm• Infection• Inflammation• Vascular• Trauma

• Congenital• Rheumatoid nodule• Lymph node• Sarcoidosis

Page 4: Spn ppt

• malignant primary lung carcinoma Primary pulmonary lymphoma Primary pulmonary carcinoid tumor Solitary metastasis

• Benign Hamartoma Chondroma

• Infectious Granuloma (tuberculous, fungal) Round pneumonia Abscess

• Noninfectious Rheumatoid arthritis Wegener granulomatosis

Page 5: Spn ppt

• Vascular Arteriovenous malformation Infarct Hematoma

• Congenital Bronchial atresia Sequestration

• Simulants of a solitary pulmonary nodule

External object (eg, nipple, mole) Pseudotumor (fluid in fissure) Pleural plaque or mass

Page 6: Spn ppt

• Standard radiologic evaluation of a suspected solitary pulmonary nodule includes careful review of findings at chest radiography and, when appropriate, comparison with findings at prior radiography, chest fluoroscopy, and CT and correlation with clinical signs and symptoms.

• The goal of radiologic evaluation of suspected solitary pulmonary nodules is to noninvasively differentiate benign from malignant lesions as accurately as possible

Page 7: Spn ppt

• Work-up of SPN: Imaging and Procedures :

• CXR• CT Scan• PET Scan• Bronchoscopy• Biopsy

– TTNA, FNA– VATS, Open

Page 8: Spn ppt

Factors Influencing Probability of Malignancy

• Size• Growth rate• Attenuation and

Enhancement on CT• Margins

• Patient age• Gender• Smoking history• Occupational history• Endemic granulomatous

disease

Page 9: Spn ppt

Evaluation of Solitary Pulmonary Nodule:

1.Determine whether the abnormality is in fact a solitary pulmonary nodule.2.Morphologic Evaluation:size, Margins, and Contour3.Internal Characteristics: Attenuation and Enhancement(soft tissue, calcification, fat & ground glass)• cavitation and airbronchogram,etc

Page 10: Spn ppt

Simulants of a solitary pulmonary nodule

Page 11: Spn ppt

Rib fracture in a 50-year-old woman with multiple myeloma

Page 12: Spn ppt

CT scan shows a healed fracture of the right second rib (arrow).

Page 13: Spn ppt

Bone island in a 61-year-old man with melanoma

Page 14: Spn ppt

Fluoroscopic images show a well-marginated intraosseous lesion (arrow)

Page 15: Spn ppt

Segmental bronchial atresia in a 17-year-old girl

Page 16: Spn ppt
Page 17: Spn ppt

multiple small nodular areas of increased attenuation bilaterally with enlarged feeding and draining vessels

Page 18: Spn ppt
Page 19: Spn ppt

Size of SPN

• Most SPN are less than 2 cm in diameter• Malignant nodules

– 40% less than 2 cm – 15% less than 1 cm – 1% less than 7 mm– 0% less than 5 mm

Page 20: Spn ppt

Growth Rate:Doubling Time

• 25% increase in diameter results in doubling of volume

• Non-malignant disease: less than 1 month or greater than 400 days

• Malignant lesions: 30 to 400 days

Page 21: Spn ppt

Margins • Corona radiata sign - highly associated with malignancy

• Lobulated or scalloped margins - intermediate probability

• Smooth margins - more likely benign unless metastatic in origin

Page 22: Spn ppt

Non-small cell lung cancer in a 61-year-old woman

Page 23: Spn ppt

Spiculated lesion

Page 24: Spn ppt

Pulmonary infarct in 65-year-old woman who presented with pleuritic chest pain

Page 25: Spn ppt

Round pneumonia in a 23-year-old woman who presented with cough and fever

Page 26: Spn ppt

Non-small cell lung cancer in a 63-year-old woman

Page 27: Spn ppt

Arteriovenous malformation in a 34-year-old man with hereditary hemorrhagic telangiectasia.

Page 28: Spn ppt
Page 29: Spn ppt
Page 30: Spn ppt

Pulmonary cyst in a 42-year-old man with emphysema who was undergoing pre-lung transplantation evaluation.

Page 31: Spn ppt
Page 32: Spn ppt
Page 33: Spn ppt

Solitary metastasis from bladder cancer in a 45-year-old woman

Page 34: Spn ppt

Attenuation and Enhancement:

•Groundglass, soft tissue, calcification & fat •Partly solid lesions with ground-glass components had a malignancy rate of 63%.

•Nonsolid - only ground-glass lesions had a malignancy rate of 18%.

•Only solid lesions had a malignancy rate of only 7%.

Page 35: Spn ppt
Page 36: Spn ppt
Page 37: Spn ppt

Calcifications:

Page 38: Spn ppt

Benign Calcification:Popcorn Calcification

Page 39: Spn ppt
Page 40: Spn ppt

Benign Calcification: Central Calcification

Page 41: Spn ppt

Non-small cell lung cancer in a 45-year-old woman

Page 42: Spn ppt

Typical pulmonary carcinoid tumor in a 68-year-old woman

Page 43: Spn ppt

• The presence of intranodular fat(attenuation, -40 to -120 HU) is a reliable indicator of a hamartoma

Page 44: Spn ppt

Squamous cell lung cancer in a 60-year-old woman

Page 45: Spn ppt

Aspergillus infection in a 48-year-old man with leukemia.

Page 46: Spn ppt

Bronchioloalveolar cell carcinoma in a 68-year-old woman

Page 47: Spn ppt

Air Bronchogram sign:air bronchogram iscommonly seen in BAC (bronchoalveolar cell

carcinoma) and adenocarcinoma.

Page 48: Spn ppt

• Malignant disease– Spiculated (primary)

• 90% malignant

– Round, smooth, and peripheral (metastatic)

• 20% malignant

– Thick walled cavity– Eccentric calcification

• Benign disease– Characteristic

calcifications– Smaller than 5 mm– Non-solid lesion 5-9 mm– Thin walled cavity– Satellite nodules– Contrast enhancement

less than 15 HU has a very high predictive value for benignity (99%).

Radiographic Characteristics

Page 49: Spn ppt

Work-up of SPN:

• Risk Factors– Smoking

• Lung cancer is 10 times more common in smokers compared to non-smokers

– History of lung cancer in a first degree relative

– Exposure to asbestos, uranium and radon.– Rare in under 35 years of age

Page 50: Spn ppt
Page 51: Spn ppt
Page 52: Spn ppt

Work-up of SPN:PET Scan

• Positron Emission Tomography• 18-FDG (fluorodeoxyglucose)

– increased uptake by metabolically active cells – does not enter glycolysis

• Allows more accurate identification of tumors, lymph nodes, and metastatic disease

• Benign disease Malignant disease – 96% sensitivity 96% sensitivity – 88% specificity 77% specificity

Page 53: Spn ppt

Limitations of PET Scans

• Spatial resolution 7-8 mm thus unreliable for lesions less than 1 cm

• False positives in infection or inflammation• False negatives in tumors with low uptake such as

bronchoalveolar cell carcinoma

Page 54: Spn ppt

Utilization of PET Scans

• PET not usually indicated unless it will change management

• PET not indicated if surgery is planned• PET not indicated with known malignancy

Page 55: Spn ppt

Work-up of SPN:Bronchoscopy

• Limited role• Transbronchial needle aspiration of mediastinal

lymph nodes • Useful for large central lesions and endobronchial

lesions• Can detect infection• No use in peripheral nodules

Page 56: Spn ppt

Work-up of SPN: Biopsy

• CT guided– Transthoracic needle aspiration (TTNA)– Fine needle aspiration (FNA)

• Surgical– Video Assisted Thoracic Surgery (VATS) – Open

Page 57: Spn ppt

Work-up of SPN:CT guided TTNA

• Increasing utilization of TTNA • Not indicated for patients committed to surgery• Accuracy for detecting malignancy 64-100%• Yield increased when cytopathologist present• Three results:

– Malignant– Specific benign, e.g. TB– Non-specific benign, e.g. bronchoalveolar hyperplasia

Page 58: Spn ppt

Work-up of SPN:CT guided TTNA

• Complications:– Pneumothorax 25%, Hemoptysis <10%

• Relative contraindications:– Pulmonary HTN, severe COPD, AVM’s, coagulopathy

• Absolute contraindication:– One lung or bilateral lung transplant

Page 59: Spn ppt

Work-up of SPN:Surgical biopsy

• VATS (Video Assisted Thoracic Surgery)– peripheral nodules within 2 cm of pleura– solid lesions– lesions not diagnosed by other means

• Open– commitment to resection with curative intent

Page 60: Spn ppt

Sample Pre-biopsy AlgorithmCHEST 2004; 125:1522-1529

CHEST 2004; 125:1522-1529

Page 61: Spn ppt

Sample Post-biopsy AlgorithmCHEST 2004; 125:1522-1529

Page 62: Spn ppt

Summary

• SPN by definition is 3 cm or less– 40% are malignant

• REVIEW PRIOR FILMS!!!• margins of the lesion and the presence or absence

of calcification should be assessed• Lesions that are unchanged in size over a 2-year

period may be presumed to be benign and followed up at 6-monthly intervals for a further 2 years.

Page 63: Spn ppt

• No change in 2 years…no further work-up• The presence of central or ringlike calcification

also places the lesion in the benign category• The presence of intranodular fat(attenuation,

-40 to -120 HU) is a reliable indicator of a hamartoma

• Contrast enhancement less than 15 HU has a very high predictive value for benignity (99%).

• TTNA for those not committed to surgery• Surgical biopsy with curative intent

Page 64: Spn ppt

Thank you